🚀 VC round data is live in beta, check it out!
Respiratorius Valuation Multiples
Discover revenue and EBITDA valuation multiples for Respiratorius and similar public comparables like Stayble Therapeutics, GeNeuro, Cannovum Cannabis, Nidhogg Resources Holding and more.
Respiratorius Overview
About Respiratorius
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
Founded
1999
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$1M
Respiratorius Financials
Respiratorius reported last fiscal year revenue of — and negative EBITDA of ($374K).
In the same fiscal year, Respiratorius generated $456K in gross profit, ($374K) in EBITDA losses, and had net loss of ($735K).
Respiratorius P&L
In the most recent fiscal year, Respiratorius reported revenue of — and EBITDA of ($374K).
Respiratorius expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | $456K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($374K) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($735K) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Respiratorius Stock Performance
Respiratorius has current market cap of $1M, and enterprise value of $1M.
Market Cap Evolution
Respiratorius' stock price is $0.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1M | $1M | 0.0% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRespiratorius Valuation Multiples
Respiratorius trades at (3.1x) EV/EBITDA.
Respiratorius Financial Valuation Multiples
As of March 30, 2026, Respiratorius has market cap of $1M and EV of $1M.
Equity research analysts estimate Respiratorius' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Respiratorius has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.5x | XXX | XXX | XXX |
| P/E | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Respiratorius Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Respiratorius Margins & Growth Rates
Respiratorius' revenue in the last fiscal year grew by —.
Respiratorius' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.2M for the same period.
Respiratorius Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (14%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Respiratorius Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stayble Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GeNeuro | XXX | XXX | XXX | XXX | XXX | XXX |
| Cannovum Cannabis | XXX | XXX | XXX | XXX | XXX | XXX |
| Nidhogg Resources Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaLundensis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Respiratorius M&A Activity
Respiratorius acquired XXX companies to date.
Last acquisition by Respiratorius was on XXXXXXXX, XXXXX. Respiratorius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Respiratorius
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRespiratorius Investment Activity
Respiratorius invested in XXX companies to date.
Respiratorius made its latest investment on XXXXXXXX, XXXXX. Respiratorius invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Respiratorius
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Respiratorius
| When was Respiratorius founded? | Respiratorius was founded in 1999. |
| Where is Respiratorius headquartered? | Respiratorius is headquartered in Sweden. |
| How many employees does Respiratorius have? | As of today, Respiratorius has over 1 employees. |
| Is Respiratorius publicly listed? | Yes, Respiratorius is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Respiratorius? | Respiratorius trades under RESP ticker. |
| When did Respiratorius go public? | Respiratorius went public in 2012. |
| Who are competitors of Respiratorius? | Respiratorius main competitors are Stayble Therapeutics, GeNeuro, Cannovum Cannabis, Nidhogg Resources Holding. |
| What is the current market cap of Respiratorius? | Respiratorius' current market cap is $1M. |
| Is Respiratorius profitable? | No, Respiratorius is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.